Singapore-based exosome manufacturer

Esco Aster is a Singapore-based Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in the production of complex biologics, including exosomes, cell and gene therapies, and vaccines. The company utilizes its proprietary 3D Tide Motion™ bioreactor technology to provide high-yield, cost-effective manufacturing solutions for adherent cell cultures. Through its 'Astericle' platform, Esco Aster offers end-to-end services for engineered exosome development, spanning from cell line engineering and process development to cGMP-compliant manufacturing. The company has established significant international partnerships, notably with Shine-On Biomedical for the clinical production of SOB100, a first-in-class HLA-G targeted exosome drug delivery platform. Esco Aster is a key enabler in Singapore's biomedical ecosystem, supporting global biotech and pharmaceutical clients in the translation of novel extracellular vesicle therapies.